Cipla Aims to Sell Copies of High-Profile Biotechnology Medicines in China and India

Strategic Insights -

Cipla Ltd., an Indian drugmaker, plans to replicate Roche Holding AG's and Amgen Inc.'s best-selling biotechnology medicines with a partner in China. This new strategy aims to make affordable copies of high-profile treatments, including Roche's Avastin and Herceptin cancer drugs, and Amgen's rheumatoid arthritis treatment Enbrel. With annual sales of $19 billion, these medications will be made more accessible to consumers at lower prices. Cipla's Chairman, Yusuf Hamied, is confident that the company's biosimilars will revolutionize the market. By acquiring stakes in companies in India and Hong Kong, Cipla will focus on monoclonal antibodies, enabling it to enter the lucrative biotechnology market.

Key Takeaways:

  • Cipla plans to partner with a Chinese company to market biosimilars of Roche's and Amgen's best-selling biotechnology medicines in India and China.
  • The company intends to sell copies of Avastin, Enbrel, and Herceptin cancer drugs, which generated $19 billion in sales last year.
  • Cipla's strategy involves marketing cheaper alternatives to high-profile treatments, with the goal of making them more accessible to consumers.
  • By investing in companies in India and Hong Kong, Cipla aims to expand its business in the high-tech, high-growth biotechnology segment.
  • The company will target 8 to 10 treatments for rheumatoid arthritis, colorectal cancer, allergic asthma, and head and neck cancer that are not covered by patents in India and China.
  • Biotechnology drugs account for 10% to 15% of the global pharmaceutical market, with many off-patent or set to lose patent protection soon.
  • Cipla will invest $65 million to acquire a 40% stake in a company based in Goa and 25% stake in a Hong Kong-based biotechnology company.

Statistics:

  • $19 billion: Annual sales of Avastin, Enbrel, and Herceptin cancer drugs
  • 8 to 10: Number of treatments that Cipla will target for rheumatoid arthritis, colorectal cancer, allergic asthma, and head and neck cancer
  • 10% to 15%: Proportion of biotechnology drugs in the global pharmaceutical market
  • 5 years: Timeframe for Cipla to achieve its goal of expanding into the biotechnology market
  • $30 billion: Annual sales of brand-name drugs in the market targeted by Cipla

Sources:

  • "Cipla Plans to Make Copies of Roche and Amgen's Biotechnology Medicines" by Euclid Infotech, distributed by Contify.com, 2010.